Sandhu Jaspreet S, Te Alexis E
Department of Urology, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021, USA.
Curr Urol Rep. 2004 Aug;5(4):274-9. doi: 10.1007/s11934-004-0050-6.
Medical treatment for the symptoms of benign prostatic hyperplasia (BPH) consists of a blockers and 5-alpha-reductase inhibitors. Data suggest that 5-alpha-reductase inhibitors can prevent progression of BPH and reduce the risk of BPH-related surgery, especially in men with large-volume prostates. Results from the largest randomized, prospective, placebo-controlled trial, the Medical Therapy of Prostatic Symptoms trial, have been presented. These results support the notion of using 5-alpha-reductase inhibitors for the prevention of BPH progression and BPH-related surgery. Furthermore, long-term 5-alpha-reductase inhibitor monotherapy, although slow in onset, is a viable therapy for symptom relief in men with mild to moderate symptoms.
良性前列腺增生（BPH）症状的医学治疗包括α受体阻滞剂和5-α还原酶抑制剂。数据表明，5-α还原酶抑制剂可预防BPH进展并降低BPH相关手术的风险，尤其是对于前列腺体积较大的男性。最大规模的随机、前瞻性、安慰剂对照试验——前列腺症状医学治疗试验的结果已经公布。这些结果支持使用5-α还原酶抑制剂预防BPH进展和BPH相关手术的观点。此外，长期5-α还原酶抑制剂单一疗法虽然起效缓慢，但对于症状轻至中度的男性而言是一种可行的缓解症状的疗法。
